얼굴용 주사제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen & PMMA Microspheres, HA), By Application (Facial Line Correction, Lip Augmentation), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

얼굴용 주사제 시장 성장과 동향

Grand View Research, Inc.의 새로운 보고서에 따르면, 세계의 얼굴용 주사제 시장 규모는 2025-2030년에 걸쳐 12.3%의 연평균 복합 성장률(CAGR)을 나타내며 2030년까지 249억 달러에 이를 전망입니다.

얼굴용 주사제는 안티 에이징 치료에서 매우 중요하며 특히 색소 침착과 조기 노화와 같은 손상을 막기 위해 사용됩니다.

특히 신흥 국가에서의 외견 중시의 개발은 시장을 견인할 것으로 예상되는 주요 요인 중 하나입니다.

팬데믹의 발생으로 2020년 1분기와 2분기에는 긴급성이 없는 미용 성형 수술이 보류되었습니다. 화장품 산업을 포함한 모든 산업에 영향을 미쳤습니다. 에스테틱 관련 제품 공급망도 영향을 받았습니다.

얼굴용 주사제 시장 보고서 하이라이트

• 제품 유형별로는 예측 기간을 통해 A형 보툴리눔툭신(보톡스) 부문이 시장을 독점할 것으로 예측됩니다.
• 용도별로는 페이스 라인 수정 부문이 시장을 독점해, 2024년에는 33.2%의 최대 수익 점유율을 차지했습니다.
• 최종 용도별로는 메드 스파 부문이 시장을 독점해, 2024년에는 47.0%의 최대 수익 점유율을 차지했습니다.
• 북미는 제품 입수가 용이하고 숙련된 외과의사가 다수 존재하기 때문에 2024년 매출액 점유율은 38.9%로 시장을 독점했습니다.
• 아시아태평양은 주요 수익 창출 거점으로 기능할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 얼굴용 주사제 시장 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 얼굴용 주사 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 얼굴용 주사제 시장 : 제품별, 추정·동향 분석

• 세계의 얼굴용 주사제 시장 : 제품 대시보드
• 세계의 얼굴용 주사제 시장 : 제품 변동 분석
• 세계의 얼굴용 주사제 시장(제품별, 수익별)
• 콜라겐 & PMMA 마이크로 스피어
• 보툴리눔 톡신 A형
• HA
• CaHA
• PLLA
• 기타

제5장 얼굴용 주사제 시장 : 용도별, 추정·동향 분석

• 세계의 얼굴용 주사제 시장 : 용도 대시보드
• 세계의 얼굴용 주사제 시장 : 용도 변동 분석
• 용도별 수익
• 얼굴 라인 교정
• 입술 확대
• 페이스 리프트
• 여드름 흉터 치료
• 지방 위축 치료
• 기타

제6장 얼굴용 주사제 시장 : 최종 용도별, 추정·동향 분석

• 세계의 얼굴용 주사제 시장 : 최종 용도 대시보드
• 세계의 얼굴용 주사제 시장 : 최종 용도 변동 분석
• 최종 용도별 수익
• 메드스파
• 피부과 클리닉
• 병원
• 기타

제7장 얼굴용 주사제 시장 : 제품, 용도, 최종 용도별, 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁의 분류
  • 주요 기업의 시장 점유율 분석(2024년)
  • Ispen
  • Abbvie
  • Medytox Inc.
  • Merz GmbH and Co. KGaA
  • Revance Therapeutics, Inc.
  • Galderma
  • Sinclair Pharma

KTH

영문 목차

영문목차

Facial Injectable Market Growth & Trends:

The global facial injectable market size is expected to reach USD 24.9 billion by 2030, registering a CAGR of 12.3% from 2025 to 2030, according to a new report by Grand View Research, Inc., The facial injectables are crucial in anti-aging treatments and are particularly used to stop damage such as hyperpigmentation and early aging. The most popular treatments across all socioeconomic groups are Botox and fillers, which have gained immense popularity.

Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

The onset of the pandemic led to nonurgent and cosmetic surgeries being put on hold in the first and second quarters of 2020. Since there were stringent restrictions imposed by the authority bodies as a precaution, the coronavirus outbreak has had an impact on every industry, including the cosmetics industry. Aesthetics-related product supply chains were also impacted. The demand-supply chain across the whole medical device sector has been severely disrupted by the pandemic.

Facial Injectable Market Report Highlights:

• Based on product, the botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popularly used minimally invasive procedures
• Based on application, the facial line correction segment dominated the market and accounted for the largest revenue share of 33.2% in 2024. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines
• Based on end-use, the medSpa segment dominated the market and held the largest revenue share of 47.0% in 2024. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals
• North America dominated the market with a revenue share of 38.9% in 2024 owing to the easy availability of the products and the presence of a large number of skilled surgeons
• The Asia Pacific region is expected to serve as a key revenue-generating center. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Facial Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing beauty consciousness among consumers
    • 3.2.1.2. Shift in consumer preference towards minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. Facial Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Facial Injectable Market: Product Estimates & Trend Analysis

• 4.1. Global Facial Injectable Market: Product Dashboard
• 4.2. Global Facial Injectable Market: Product Movement Analysis
• 4.3. Global Facial Injectable Market by Product, Revenue
• 4.4. Collagen & PMMA Microspheres
  • 4.4.1. Collagen & PMMA microspheres market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Botulinum Toxin Type A
  • 4.5.1. Botulinum toxin Type A market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. HA
  • 4.6.1. HA market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. CaHA
  • 4.7.1. CaHa market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. PLLA
  • 4.8.1. PLLA market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Facial Injectable Market: Application Estimates & Trend Analysis

• 5.1. Global Facial Injectable Market: Application Dashboard
• 5.2. Global Facial Injectable Market: Application Movement Analysis
• 5.3. Global Facial Injectable Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Facial Line Correction
  • 5.4.1. Facial line correction market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Lip Augmentation
  • 5.5.1. Lip augmentation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Face Lift
  • 5.6.1. Face lift market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Acne Scar Treatment
  • 5.7.1. Acne scar treatment market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Lipoatrophy Treatment
  • 5.8.1. Lipoatrophy treatment market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Facial Injectable Market: End Use Estimates & Trend Analysis

• 6.1. Global Facial Injectable Market: End use Dashboard
• 6.2. Global Facial Injectable Market: End use Movement Analysis
• 6.3. Global Facial Injectable Market Estimates and Forecasts, by End use, Revenue (USD Million)
• 6.4. MedSpa
  • 6.4.1. MedSpa market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Dermatology Clinics
  • 6.5.1. Dermatology Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Facial Injectable Market: Regional Estimates & Trend Analysis by Product, Application, and End use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
  • 8.1.1. Key company market share analysis, 2024
  • 8.1.2. Ispen
    • 8.1.2.1. Company overview
    • 8.1.2.2. Financial performance
    • 8.1.2.3. Product benchmarking
    • 8.1.2.4. Strategic initiatives
  • 8.1.3. Abbvie
    • 8.1.3.1. Company overview
    • 8.1.3.2. Financial performance
    • 8.1.3.3. Product benchmarking
    • 8.1.3.4. Strategic initiatives
  • 8.1.4. Medytox Inc.
    • 8.1.4.1. Company overview
    • 8.1.4.2. Financial performance
    • 8.1.4.3. Product benchmarking
    • 8.1.4.4. Strategic initiatives
  • 8.1.5. Merz GmbH and Co. KGaA
    • 8.1.5.1. Company overview
    • 8.1.5.2. Financial performance
    • 8.1.5.3. Product benchmarking
    • 8.1.5.4. Strategic initiatives
  • 8.1.6. Revance Therapeutics, Inc.
    • 8.1.6.1. Company overview
    • 8.1.6.2. Financial performance
    • 8.1.6.3. Product benchmarking
    • 8.1.6.4. Strategic initiatives
  • 8.1.7. Galderma
    • 8.1.7.1. Company overview
    • 8.1.7.2. Financial performance
    • 8.1.7.3. Product benchmarking
    • 8.1.7.4. Strategic initiatives
  • 8.1.8. Sinclair Pharma
    • 8.1.8.1. Company overview
    • 8.1.8.2. Financial performance
    • 8.1.8.3. Product benchmarking
    • 8.1.8.4. Strategic initiatives

관련자료